Daily Endocrinology Research Analysis
Analyzed 57 papers and selected 3 impactful papers.
Summary
Key advances today span therapeutic, genetic, and mechanistic endocrinology: a phase 3 RCT shows finerenone significantly lowers albuminuria in adults with type 1 diabetes and CKD; first-in-human in vivo adenine base editing targeting PCSK9 enters clinical testing for familial hypercholesterolemia; and a mechanistic study links intrauterine hyperglycemia to epigenetically driven GABA–somatostatin signaling changes in fetal islets that may program offspring glucose intolerance.
Research Themes
- Diabetic kidney disease therapy with mineralocorticoid receptor antagonism
- In vivo base editing of PCSK9 for durable LDL-C lowering
- Developmental programming of metabolism via epigenetic remodeling
Selected Articles
1. Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
In this phase 3 randomized, placebo-controlled trial of 242 adults with type 1 diabetes and CKD, finerenone reduced urinary albumin-to-creatinine ratio by 34% over 6 months versus 12% with placebo, yielding a 25% greater reduction (P<0.001). Hyperkalemia was the most common adverse event (10.1% vs 3.3%), with 1.7% discontinuing finerenone due to hyperkalemia.
Impact: This is the first phase 3 RCT to demonstrate renal biomarker benefit of finerenone in type 1 diabetes with CKD, extending prior evidence from type 2 diabetes. The findings may inform future guideline updates for albuminuric CKD in type 1 diabetes.
Clinical Implications: Finerenone may be considered to reduce albuminuria in adults with type 1 diabetes and CKD, with careful potassium monitoring. Confirmation on hard renal and cardiovascular outcomes and longer-term eGFR trajectories is needed before broad adoption.
Key Findings
- Finerenone achieved a 34% reduction in UACR over 6 months vs 12% with placebo.
- The between-group effect corresponded to a 25% greater reduction with finerenone (P<0.001).
- Hyperkalemia occurred in 10.1% (finerenone) vs 3.3% (placebo); 1.7% discontinued due to hyperkalemia.
Methodological Strengths
- Randomized, placebo-controlled phase 3 design with prespecified clinicaltrials.gov registration (NCT05901831).
- Clinically relevant biomarker endpoint (UACR) with robust statistical significance.
Limitations
- Short 6-month follow-up focused on albuminuria rather than hard renal outcomes.
- Modest sample size and increased hyperkalemia risk may limit generalizability.
Future Directions: Evaluate long-term renal and cardiovascular outcomes, optimal potassium management strategies, and subgroup effects (e.g., baseline eGFR, albuminuria strata) in type 1 diabetes CKD.
BACKGROUND: The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The efficacy and safety of finerenone in persons with type 1 diabetes and CKD are unknown. METHODS: We conducted a phase 3 trial involving adults who had type 1 diabetes, CKD (estimated glomerular filtration rate [eGFR], 25 to <90 ml per minute per 1.73 m RESULTS: A total of 242 participants underwent randomization. The median urinary albumin-to-creatinine ratio decreased from 574.6 at baseline to 373.5 at 6 months among all the participants assigned to receive finerenone and from 506.4 to 475.6 among those assigned to receive placebo. Over a period of 6 months, the urinary albumin-to-creatinine ratio decreased by 34% with finerenone (geometric mean ratio to baseline, 0.66; 95% confidence interval [CI], 0.60 to 0.73) and 12% with placebo (geometric mean ratio to baseline, 0.88; 95% CI, 0.79 to 0.98), which corresponded to a 25% greater reduction with finerenone than with placebo (geometric mean ratio for finerenone vs. placebo, 0.75; 95% CI, 0.65 to 0.87; P<0.001). The most common adverse event was hyperkalemia (in 12 participants [10.1%] with finerenone and in 4 [3.3%] with placebo); 2 participants (1.7%) discontinued finerenone because of hyperkalemia. At 6 months, the change in the eGFR was -5.6 ml per minute per 1.73 m CONCLUSIONS: In adults with type 1 diabetes and CKD, finerenone resulted in a significantly greater decrease in the urinary albumin-to-creatinine ratio than placebo. (Funded by Bayer; FINE-ONE ClinicalTrials.gov number, NCT05901831.).
2. Epigenetically regulated pancreatic GABA-somatostatin signaling underlies gestational diabetes-induced glucose intolerance in offspring.
The study implicates intrauterine hyperglycemia in epigenetically reprogramming fetal pancreatic islets by downregulating TET2/3 and increasing methylation of a GABA synthesis gene, pointing to altered GABA–somatostatin signaling as a mechanism for offspring glucose intolerance. These data provide a mechanistic link between maternal GDM and intergenerational metabolic risk.
Impact: Revealing an epigenetic pathway connecting maternal hyperglycemia to offspring islet signaling advances the developmental origins of health and disease framework and identifies testable nodes (TET2/3–GABA–somatostatin axis) for intervention.
Clinical Implications: While preclinical, the findings suggest that preventing maternal hyperglycemia and exploring epigenetic or islet signaling–targeted interventions could mitigate intergenerational diabetes risk.
Key Findings
- Intrauterine hyperglycemia downregulated DNA demethylases TET2/3 in fetal pancreatic islets.
- DNA methylation of a GABA synthesis gene was increased under intrauterine hyperglycemia.
- Results implicate altered pancreatic GABA–somatostatin signaling as a driver of offspring glucose intolerance.
Methodological Strengths
- Mechanistic focus on epigenetic regulators (TET2/3) in fetal pancreatic islets.
- Identification of a defined signaling axis (GABA–somatostatin) linking maternal environment to offspring metabolism.
Limitations
- Preclinical mechanistic study with limited detail on human validation in the abstract.
- Causal links to long-term metabolic phenotypes require further in vivo and clinical confirmation.
Future Directions: Validate the TET2/3–GABA–somatostatin axis in human tissues and cohorts, and test whether maternal glycemic control or targeted epigenetic modulation can normalize islet signaling and offspring metabolic outcomes.
Gestational diabetes mellitus (GDM) can increase the risk for diabetes in offspring, but the mechanisms underlying the effects of intrauterine hyperglycemia (IHG) on the fetus remain unknown. Here, we show that IHG down-regulated DNA demethylases TET2/3 in fetal pancreatic islets, increased DNA methylation of γ-aminobutyric acid (GABA) synthesis gene
3. In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial.
This ongoing first-in-human phase 1 study tests a single-dose, GalNAc–LNP-delivered adenine base editor (YOLT-101) targeting PCSK9 in adults with heterozygous familial hypercholesterolemia. Interim data include dose escalation across six participants and assessment of safety/tolerability with secondary endpoints of PCSK9 and LDL-C lowering.
Impact: Represents a milestone for in vivo base editing in metabolic disease, potentially enabling one-time, durable LDL-C lowering in high-risk patients where adherence and access to biologics can be limiting.
Clinical Implications: If safety and durable LDL-C reduction are confirmed, base editing of PCSK9 could offer a transformative, single-dose alternative to chronic lipid-lowering therapies for familial hypercholesterolemia.
Key Findings
- YOLT-101 employs adenine base editing delivered via GalNAc-modified lipid nanoparticles to inactivate PCSK9.
- Interim phase 1 results include six participants receiving single intravenous doses at 0.2, 0.4, or 0.6 mg/kg.
- Primary endpoints are safety and tolerability; secondary endpoints include lowering of PCSK9 and LDL-C levels.
Methodological Strengths
- First-in-human, dose-escalation clinical study of in vivo base editing for a common metabolic disorder.
- Targeted hepatic delivery using GalNAc–LNP platform aligned with mechanistic rationale for PCSK9 inactivation.
Limitations
- Interim, small sample size (n=6) with early safety focus; efficacy durability not yet established.
- Open-label design without a control group limits inference on comparative efficacy.
Future Directions: Expand enrollment with longer follow-up to assess durability, off-target effects, and cardiovascular outcomes; compare with existing PCSK9 inhibitors and inclisiran in head-to-head or pragmatic designs.
Heterozygous familial hypercholesterolemia is a common genetic disorder characterized by lifelong elevation of serum low-density lipoprotein cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. YOLT-101 is an investigational in vivo gene therapy that uses adenine base-editing technology, delivered via GalNAc-modified lipid nanoparticles to inactivate PCSK9 and achieve sustained LDL-C reduction. Here we report interim results from an ongoing clinical trial evaluating primary (safety and tolerability) and secondary (lowering of PCSK9 and LDL-C levels) outcomes of a single intravenous dose of YOLT-101 in adults with heterozygous familial hypercholesterolemia and uncontrolled LDL-C. Six participants (three men and three women) received escalating doses of YOLT-101 (0.2, 0.4 or 0.6 mg kg